OFA in Thoracic Surgery

Sponsor
Shanghai Zhongshan Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05063396
Collaborator
(none)
60
2
2
50
30
0.6

Study Details

Study Description

Brief Summary

to investigate the efficacy and safety of opioid-free anesthesia for non-small-cell lung cancer resection and its underlying clinical value

Condition or Disease Intervention/Treatment Phase
  • Procedure: opioid free anesthesia
  • Procedure: Opioid-sparing anesthesia
N/A

Detailed Description

Opioids used to have its irreplaceable role in standard opioid-based anesthesia, yet with the help of hypnotics, local anesthetics, anti-inflammatory drugs, α-2 agonists and epidural techniques, opioid-free anesthesia (OFA) has been proved to be safe and feasible for non-cardiac major surgeries. Opioid-sparing anesthesia (OSA) is encouraged by the needs of enhanced recovery and recommended by the latest guidelines for anesthesia of lung surgery. According to previous studies, both opioid-sparing and opioid-free anesthesia would reduce the incidence of opioid-related adverse events and speed up the postoperative recovery to some extent, yet no studies ever are dedicated to compare these two different techniques.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
The Efficacy and Safety of Opioid-free Anesthesia(OFA) for Non-small-cell Lung Cancer Resection and Its Underlying Clinical Value: a Prospective Study
Actual Study Start Date :
Oct 1, 2021
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: opioid free anesthesia

opioid free anesthesia

Procedure: opioid free anesthesia
Instead of use of large amount of opioids for intraoperative stress response and postoperative pain controlling, during the whole perioperative period patients received no opioid at all. intravenous local anesthetics and thoracic epidural were used.

Placebo Comparator: Opioid-sparing anesthesia

Opioid-sparing anesthesia

Procedure: Opioid-sparing anesthesia
patients will receive opioid-sparing anesthesia protocol with minimal intraoperative sufentanil, remifentanil and epidural hydromorphone.

Outcome Measures

Primary Outcome Measures

  1. acute postoperative pain scores [day1 postoperation]

    visual analog scale was used

  2. acute postoperative pain scores [day2 postoperation]

    visual analog scale was used

  3. occurrence of postoperative opioid-related adverse events [day1 postoperation]

    occurrence of postoperative opioid-related adverse events

  4. occurrence of postoperative opioid-related adverse events [day2 postoperation]

    occurrence of postoperative opioid-related adverse events

Secondary Outcome Measures

  1. relapse free survival and overall survival [within 5 years]

    relapse free survival and overall survival

  2. occurrence of episodes of postoperative pain (VAS ≥4) [within 48hours]

    occurrence of episodes of postoperative pain (VAS ≥4)

  3. PCEA bolus consumption [within 48hours]

    PCEA bolus consumption

  4. need for rescue intravenous opioids or any type of painkiller [within 48hours]

    need for rescue intravenous opioids or any type of painkiller

  5. hospital length of stay and total hospital expenses [within 10days]

    hospital length of stay and total hospital expenses

  6. Pathologic results and TNM rating [within one month]

    Pathologic results and TNM rating

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • going through thoracoscopic lung surgery including lobectomy, segmentectomy, single or multiple wedge resection, and two of the above procedures combined;

  • able to complete the pain scoring face-to-face;

  • no cognitive dysfunction or history of anesthetic drug allergy;

  • ASA grade I-II

Exclusion Criteria:

-psychological disorders

Contacts and Locations

Locations

Site City State Country Postal Code
1 180 Fenglin Road Shanghai China 200032
2 Zhongshan Hospital Shanghai China

Sponsors and Collaborators

  • Shanghai Zhongshan Hospital

Investigators

  • Study Chair: Changhong Miao, Shanghai Zhongshan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Shanghai Zhongshan Hospital
ClinicalTrials.gov Identifier:
NCT05063396
Other Study ID Numbers:
  • OFAbywang
First Posted:
Oct 1, 2021
Last Update Posted:
Apr 27, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Shanghai Zhongshan Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 27, 2022